Stanford Neurology & Neurological Sciences
Welcome to our Department, a recognized center of excellence in neurology and neurosurgical care for over four decades. With a dedicated team of over 140 faculty members and access to four premier teaching hospitals, we are committed to advancing patient care through cutting-edge treatments and innovative research. Our state-of-the-art Stanford Health Care facility, opened in 2019, features over 600 beds and is consistently ranked among the top programs in California. We offer a comprehensive range of services, including a unique outpatient Stanford Neuroscience Health Center and numerous clinics across Northern California, accommodating over 60,000 outpatient visits annually. Our commitment to excellence is further exemplified by our partnerships with Lucile Packard Children’s Hospital, the VA Palo Alto Health Care System, and Santa Clara Valley Medical Center, ensuring compassionate care for a diverse patient population. As we continue to grow alongside the vibrant Northern California community, we remain at the forefront of neurological care, delivering innovative solutions and fostering a culture of education and research.
Antonio Omuro, MD, FAAN
Chair, Department of Neurology and Neurological Sciences
Joseph D. Grant Professor and Professor of Neurology
Neurology News
Inside the hunt to prevent, delay, and cure Alzheimer’s disease
Four Stanford efforts to better detect, understand, and defeat Alzheimer’s disease are examined. Michael Greicius, MD, MPH, discusses a rare APOE variant that may point toward new treatments. Elizabeth Mormino, PhD, and Tony Wyss-Coray, PhD, describe the Stanford Aging and Memory Study and the search for what makes some brains resilient. Katrin Andreasson, MD, explains how inflammation may deprive the brain of energy, and Frank M. Longo, MD, PhD, discusses efforts to protect synaptic connections. Sharon Sha, MD, MS, chief of the Memory Disorders Division, also comments.
Stanford Maps Insular Cortex: The Brain’s Hidden Feeling Center
A Stanford Medicine team led by Parvizi Lab has produced the most detailed map to date of the human insular cortex, detailing its organization, subregional communication, and connections to the rest of the brain. Using direct brain recordings and electrical stimulation in 87 epilepsy patients over 15 years, the study reveals a hierarchical layout: the posterior insula processes pain and temperature, the middle handles visceral sensations and can evoke anxiety, and the anterior region acts as a powerful top-down controller linked with the prefrontal cortex. The Nature paper offers an anatomically precise roadmap for targeted neuromodulation therapies with implications for chronic pain and anxiety disorders.
Bio-X Interdisciplinary Initiatives Program Seed Grant Awarded
Stroke affects over 12 million people globally each year and leaves the most survivors with long-term disability, creating a strong need for stroke recovery therapies. Dr. Paul George has received a collaborative 2026 BioX Seed grant award with a great team including Dr. Calvin Kuo (Medicine), Mark Levenston (Mechanical Engineering) and Rob Dodd (Neurosurgery). This project aims to develop a polymeric platform with individual stem cell control as a new method to improve neural repair.
Dr. Kyan Younes Receives Funding from Alzheimer’s Association via Part the Cloud
Part the Cloud, a global research funding initiative for the Alzheimer's Association, announced nearly $7 million to speed promising therapies into human trials. A Phase IIa study of bumetanide, an FDA-approved diuretic, led by Stanford neurologist Kyan Younes, is being supported with a $1 million grant, following initial support from the Knight Initiative for Brain Resilience at Stanford. Lab studies have suggested bumetanide may influence brain biology linked to the APOE gene, and health-record data have hinted it could be associated with a lower risk of Alzheimer’s in older adults.
Biological age versus chronological age: What the science says
Tony Wyss-Coray, PhD, professor of neurology and neurological sciences, joins other Stanford Medicine researchers in explaining what biological age tests can and can't tell you. The piece covers how scientists measure biological age — through epigenetic clocks, blood proteins, gene transcription, telomere length, and metabolites — and cautions against putting too much stock in commercial biological age tests, which lack FDA approval and can vary significantly depending on what they measure.
Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows
Michelle Monje, MD, PhD, the Milan Gambhir Professor in Pediatric Neuro-Oncology and professor of neurology, led research showing that levetiracetam, an existing anti-seizure medication, slows the growth of diffuse midline gliomas by disrupting the tumors' electrical connections to healthy neurons. Patients who received the drug survived longer on average, and researchers are now planning clinical trials to test it further.
Tony Wyss-Coray Is Measuring Biological Age One Organ at a Time
Tony Wyss-Coray, PhD, D.H. Chen Distinguished Professor of Neurology and Neurological Sciences, is named a Time Longevity Leader for 2026 for his development of blood tests that reveal the biological ages of individual organs, including the brain. His research links organ-specific aging to disease and mortality risk.
Stanford Medicine researchers awarded $16 million for testing dementia treatment
Sharon Sha, MD, MS, chief of the Memory Disorders Division, leads a Stanford Medicine team awarded approximately $16 million by the National Institutes of Health to support a phase 2 clinical trial assessing donanemab, an Alzheimer's medication, for treating patients with dementia with Lewy bodies.
Science Friday Podcast: Why is brain cancer so hard to treat?
Michelle Monje, MD, PhD, professor of pediatric neuro-oncology, discusses the challenges of treating brain cancer and her two decades of research on how brain tumors form and interact with healthy brain cells, in this episode of Science Friday.
Emmanuel Mignot receives Lasker Award for discovering cause of narcolepsy
Through genetic and immunological studies, the Stanford Medicine sleep researcher Emmanuel Mignot, MD, PhD found that narcolepsy stems from a deficiency of orexin in the brain, opening the door to new sleep therapies.
Learning Lab Podcast, Ep. 6: Shaping the Preclerkship Curriculum with Dr. Rebecca Miller-Kuhlmann
Rebecca Miller-Kuhlmann, MD, clinical associate professor of neurology and neurological sciences and assistant dean for pre-clerkship education, joins the Stanford Medicine EdTech team's Learning Lab podcast to discuss her strategies for teaching the pre-clerkship curriculum in a rapidly changing medical education landscape.
Henry J. Kaiser Family Foundation Teaching Award for Outstanding and Innovative Contributions to Medical Education
Stanford Medicine congratulates Scheherazade Le, MD, Clinical Professor of Adult Neurology, on receiving the Henry J. Kaiser Family Foundation Teaching Award for Outstanding and Innovative Contributions to Medical Education. The honor recognizes innovative teaching, mentoring, and research in medical education, supported by the Kaiser Family Foundation, and Dr. Le’s leadership embodies Stanford Medicine’s commitment to advancing education and patient care.
Breakdown of immune cells’ interaction is key driver in aging, study finds
Stanford Medicine researchers have identified a key driver of aging: a breakdown in how immune cells clean up after each other. As we age, tissue-resident macrophages lose their ability to clear out worn-out neutrophils, letting inflammation build across the body. Blocking a single receptor on these macrophages kept mice's organs, including the brain, heart and liver, looking and functioning younger, and slowed cognitive decline. The findings point to a possible drug target for extending healthy aging.
Biological age of our organs and cell types within them predict our disease risk, longevity
A new study led by Tony Wyss-Coray, PhD, professor of neurology and neurological sciences and director of the Knight Initiative for Brain Resilience, found that a blood test measuring the "biological age" of 11 organ systems can predict disease risk and mortality, with the brain emerging as the single strongest predictor of how long a person will live. Drawing on blood protein data from nearly 45,000 UK Biobank participants tracked for up to 17 years, the team found that people with an extremely aged brain had a 182% higher risk of dying within 15 years, while those with an extremely youthful brain had a 40% lower risk. An aged brain was also linked to roughly triple the risk of developing Alzheimer's disease. Wyss-Coray and his team hope the test could eventually help doctors identify at-risk patients and intervene before disease sets in.